ADPT President and COO Julie Rubinstein Sells $304K of Stock

Adaptive Biotechnologies Corporation President and COO Julie Rubinstein sold 11,881 shares of the company on October 15, 2026. The transaction was disclosed in a Form 4 filing with the SEC. The shares were sold at a price of $25.61 each, for a total value of $304,272.41.

Inside Julie Rubinstein's ADPT Trade

The sale was executed under a pre-arranged Rule 10b5-1 trading plan. Following the transaction, Rubinstein directly held 377,802 shares of the company. This move reduced her stake by 3.05%. It marks another scheduled sale for the executive, who also executed transactions on October 9, October 12, and October 13, 2026.

Other Institutional Activity in Adaptive Biotechnologies

Viking Global Investors, L.P. kept its stake steady with 29,993,708 shares valued at $720,448,879. Shaw D.E. & Co., Inc. grew its holdings by 2,660,252 shares, ending with 4,625,859 shares worth about $111,113,135 after a 135.3% increase. Westfield Capital Management Co LP reduced its position by 1,168,845 shares, winding up with 4,267,645 shares valued at roughly $102,508,834 following a 21.5% decrease.

Adaptive Biotechnologies Corporation Stock Down 5.4%

Adaptive Biotechnologies shares recently traded around $24.19 as of October 17, 2026, sitting 5.4% below their close of $25.58 on the day of the trade. The stock rests 7.5% below its 50-day moving average of $26.17, yet remains 26.7% above its 200-day average of $19.10. The recent price is 21.3% below its 52-week high of $30.74 and 101.6% above its 52-week low of $12.00.

Recent Earnings

For the trailing twelve months, the company generated $308,080,992 in revenue alongside an earnings per share of -$0.41. Profitability metrics show a net margin of -20.7% and a return on equity of -38.8%, while year-over-year revenue grew 21.5%. The company is not currently profitable, meaning it has no meaningful price-to-earnings ratio. Its next quarterly financial update is slated for November 4, 2026.

Insider Buying and Selling at Adaptive Biotechnologies Corporation

Insiders have been active in recent months, including a purchase by Chief Commercial Ofc Imm Med Sharon Benzeno of 103,295 shares on June 29, 2026, at $7.28 per share for a total value of $751,605.41. Rubinstein also completed several planned sales in October prior to this transaction, including 11,881 shares sold on October 9 at $26.41, 11,881 shares sold on October 12 at $25.51, and 11,881 shares sold on October 13 at $25.50.

Analysts Set New Price Targets

Wall Street firms have updated their stances on the diagnostics company. BTIG maintained a Buy rating and lifted its target to $34.00 from $25.00 on September 22, 2026. Goldman Sachs initiated coverage with a Buy rating and a $35.00 price target on September 29, 2026. Guggenheim kept a Buy rating and raised its target from $25.00 to $32.00 on October 1, 2026. TD Cowen maintained a Buy rating while moving its target from $28.00 to $32.00 on October 13, 2026, and Morgan Stanley maintained an Equal-Weight rating while bumping its target from $22.00 to $27.00 on the same day. Overall, the stock carries a consensus strong buy rating from eight analysts with a mean price target of $29.81.

About Adaptive Biotechnologies Corporation

Adaptive Biotechnologies Corporation is a commercial-stage healthcare firm based in Seattle, Washington. The company builds an immune medicine platform focused on diagnosing and treating various diseases. By combining proprietary chemistry, computational biology, and machine learning, its immunomics platform decodes the adaptive immune system to generate clinical data.

Bottom Line

Executive transactions executed through pre-arranged plans provide routine liquidity for management without signaling shifts in company strategy. Investors will look toward the upcoming financial results on November 4, 2026, to gauge ongoing revenue trends and operational progress.